Your source for biopharma news and jobs
Des Moines, IA
- Tweets 38,217
- Following 2,918
- Followers 25,956
- Likes 4,653
Nektar Therapeutics has been awarded $90 million in damages after a jury sided with the biotech, which had accused Big Pharma Eli Lilly of “botching” an analysis of their formerly partnered autoimmune drug.
hubs.li/Q04yklyK0
482
Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.
hubs.li/Q04yk8Y_0
1
1
2
594
Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.
hubs.li/Q04yk5Lv0
3
1
610
Genentech’s agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.
hubs.ly/Q04yjVds0
2
4
573
FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”
hubs.li/Q04yjwNV0
1
7
500
In Thursday’s Senate committee meeting, FDA commissioner nominee Heidi Overton was repeatedly questioned about her ability to retain the FDA’s independence under President Donald Trump, as well as her views on vaccines and abortion drugs.
hubs.li/Q04yjwGg0
541
While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body dementia.
hubs.li/Q04ydl_s0
1
4
667
Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
hubs.li/Q04yddT80
1
7
599
Kyverna Therapeutics’ miv-cel showed improved mobility and a favorable safety profile at 1 year in patients with stiff person syndrome, derisking an upcoming FDA application, William Blair said on Thursday. The biotech will seek priority review this year.
hubs.li/Q04yd0Hp0
1
1
9
856
The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.
hubs.li/Q04yc-ny0
1
3
607
Basecamp Research joins the growing group of AI-forward biotechs that in recent months have brought in notable sums from investors, including Isomorphic Labs and Enveda.
hubs.li/Q04ycQNf0
4
642
The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.
hubs.li/Q04ycQlz0
1
1
561
InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8 billion for Centessa Pharmaceuticals in March.
hubs.li/Q04ycQ960
3
4
605
Biotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.
hubs.li/Q04ycPXx0
4
568
On Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America, and Sabine Brookman-May, VP & head of Global Clinical Development, about radioligand therapy’s momentum & potential to improve care for 14M+ patients.
hubs.li/Q04ycPL80
1
5
534
While artificial intelligence can help biotech and pharma companies more quickly vet job applicants, it can also turn off the very people they want to employ. Two recruiting experts discuss AI’s role and limitations in the hiring process.
hubs.li/Q04ycMgz0
2
4
480
After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from the indication and looking to other high priority programs for the drug in neurology, endocrinology and rheumatology.
hubs.li/Q04y7Z6W0
1
2
653
Tech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.
hubs.li/Q04y8nZy0
2
4
689
Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.
hubs.li/Q04y6-g10
1
4
616
A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.
hubs.li/Q04y6ZQk0
6
785